ArticleThe Journal of experimental medicine2001
Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis.
Article in The Journal of experimental medicine, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
115 citing papers in PubMed, 290 citations in OpenAlex.
- Diverse NKT cells regulate early inflammation and neurological outcomes after cardiac arrest and resuscitation.Science translational medicine · 2024Article
- The immune system in neurological diseases: What innate-like T cells have to say.The Journal of allergy and clinical immunology · 2024Review
- Effects of Psychological Stress on Multiple SclerosisCNS & neurological disorders drug targets · 2024Review
- Unconventional T cells in brain homeostasis, injury and neurodegeneration.Frontiers in immunology · 2023Review
- Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosis.Frontiers in immunology · 2023Review
- Article
- Sphingolipid Players in Multiple Sclerosis: Their Influence on the Initiation and Course of the Disease.International journal of molecular sciences · 2022Review
- Modulation of TCR signalling components occurs prior to positive selection and lineage commitment in iNKT cells.Scientific reports · 2021Article
- Transcriptome and Function of Novel Immunosuppressive Autoreactive Invariant Natural Killer T Cells That Are Absent in Progressive Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2021Article
- NKT and NKT-like Cells in Autoimmune Neuroinflammatory Diseases-Multiple Sclerosis, Myasthenia Gravis and Guillain-Barre Syndrome.International journal of molecular sciences · 2021Review
- New Insights into Multiple Sclerosis Mechanisms: Lipids on the Track to Control Inflammation and Neurodegeneration.International journal of molecular sciences · 2021Review
- The Role of NKT Cells in Glioblastoma.Cells · 2021Review
- Connecting Neuroinflammation and Neurodegeneration in Multiple Sclerosis: Are Oligodendrocyte Precursor Cells a Nexus of Disease?Frontiers in cellular neuroscience · 2021Review
- Expression of CD1d by astrocytes corresponds with relative activity in multiple sclerosis lesions.Brain pathology (Zurich, Switzerland) · 2020Article
- Distinct PLZFJournal of immunology (Baltimore, Md. : 1950) · 2019Article
- Innate, innate-like and adaptive lymphocytes in the pathogenesis of MS and EAE.Cellular & molecular immunology · 2019Review
- NKT Cells in Neurological Diseases.Frontiers in cellular neuroscience · 2019Review
- Abrogation of Endogenous Glycolipid Antigen Presentation on Myelin-Laden Macrophages by D-Sphingosine Ameliorates the Pathogenesis of Experimental Autoimmune Encephalomyelitis.Frontiers in immunology · 2019Article
- Therapeutic Potential of Invariant Natural Killer T Cells in Autoimmunity.Frontiers in immunology · 2018Review
- The Role of Invariant NKT in Autoimmune Liver Disease: Can Vitamin D Act as an Immunomodulator?Canadian journal of gastroenterology & hepatology · 2018Review
55 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer (NK) T cells recognize lipid antigens in the context of the major histocompatibility complex (MHC) class 1-like molecule CD1 and rapidly secrete large amounts of the cytokines interferon (IFN)-gamma and interleukin (IL)-4 upon T cell receptor (TCR) engagement. We have asked whether NK T cell activation influences adaptive T cell responses to myelin antigens and their ability to cause experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis. While simultaneous activation of NK T cells with the glycolipid alpha-galactosylceramide (alpha-GalCer) and myelin-reactive T cells potentiates EAE in B10.PL mice, prior activation of NK T cells protects against disease. Exacerbation of EAE is mediated by an enhanced T helper type 1 (Th1) response to myelin basic protein and is lost in mice deficient in IFN-gamma. Protection is mediated by immune deviation of the anti-myelin basic protein (MBP) response and is dependent upon the secretion of IL-4. The modulatory effect of alpha-GalCer requires the CD1d antigen presentation pathway and is dependent upon the nature of the NK T cell response in B10.PL or C57BL/6 mice. Because CD1 molecules are nonpolymorphic and remarkably conserved among different species, modulation of NK T cell activation represents a target for intervention in T cell-mediated autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.